文献速递药物相互作用药物不良反应与药物警戒

恩考拉非尼对安非他酮、瑞舒伐他汀及粪卟啉I影响的临床评价及他汀联用考量

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
PubMed 文献 · Clin Pharmacokinet · 2024-02-29

本研究通过临床药物相互作用试验评估恩考拉非尼对CYP2B6底物安非他酮和OATP1B1/3及BCRP底物瑞舒伐他汀的影响,并测量内源性OATP1B1底物粪卟啉I以解析转运体机制。结果显示安非他酮暴露未增加,瑞舒伐他汀Cmax和AUC分别增加约2.7倍和1.6倍,粪卟啉I升高轻微,提示恩考拉非尼主要抑制BCRP,可能轻度抑制OATP1B1/3,联用他汀时需考虑换药或减量。

要点

  • 恩考拉非尼不引起临床相关CYP2B6诱导或抑制,安非他酮暴露未增加。
  • 恩考拉非尼是BCRP抑制剂,可能轻度抑制OATP1B1/3,瑞舒伐他汀Cmax和AUC分别增加约2.7倍和1.6倍。
  • 联用恩考拉非尼时可能需要更换他汀或减少他汀剂量,普伐他汀相互作用潜力最小。

核心结论

  • 恩考拉非尼不引起临床相关CYP2B6诱导或抑制,但为BCRP抑制剂并可能轻度抑制OATP1B1/3。
  • 与恩考拉非尼联用可能需要更换他汀或相应减少他汀剂量。

研究设计与样本

  • 药物相互作用研究:参与者在第-7、1、14天单次口服瑞舒伐他汀10 mg和安非他酮75 mg,并从第1天起连续服用恩考拉非尼450 mg QD和比美替尼45 mg BID。
  • 粪卟啉I数据来自接受恩考拉非尼300 mg QD和西妥昔单抗(初始400 mg/m2,后续250 mg/m2 QW)的3期研究参与者。
  • 采用非房室和房室方法进行药代动力学和药效学分析。

主要发现

  • 重复给予恩考拉非尼和比美替尼后,安非他酮暴露未增加。
  • 瑞舒伐他汀Cmax和AUC分别增加约2.7倍和1.6倍。
  • 粪卟啉I升高轻微,提示恩考拉非尼对瑞舒伐他汀的主要影响通过BCRP。

关键数值与推荐

  • 根据代谢和转运体特征对他汀分类,普伐他汀与恩考拉非尼联用时相互作用潜力最小。

临床怎么用

  • 与恩考拉非尼联用时应评估他汀选择,可能需要换用普伐他汀或减少他汀剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Encorafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma or metastatic colorectal cancer, respectively, with selected BRAF V600 mutations. A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of encorafenib on rosuvastatin, a sensitive substrate of OATP1B1/3 and breast cancer resistance protein (BCRP), and bupropion, a sensitive CYP2B6 substrate. Coproporphyrin I (CP-I), an endogenous substrate for OATP1B1, was measured in a separate study to deconvolute the mechanism of transporter DDI. METHODS: DDI study participants received a single oral dose of rosuvastatin (10 mg) and bupropion (75 mg) on days - 7, 1, and 14 and continuous doses of encorafenib (450 mg QD) and binimetinib (45 mg BID) starting on day 1. The CP-I data were collected from participants in a phase 3 study who received encorafenib (300 mg QD) and cetuximab (400 mg/m2 initial dose, then 250 mg/m2 QW). Pharmacokinetic and pharmacodynamic analysis was performed using noncompartmental and compartmental methods. RESULTS: Bupropion exposure was not increased, whereas rosuvastatin Cmax and area under the receiver operating characteristic curve (AUC) increased approximately 2.7 and 1.6-fold, respectively, following repeated doses of encorafenib and binimetinib. Increase in CP-I was minimal, suggesting that the primary effect of encorafenib on rosuvastatin is through BCRP. Categorization of statins on the basis of their metabolic and transporter profile suggests pravastatin would have the least potential for interaction when coadministered with encorafenib. CONCLUSION: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03864042, registered 6 March 2019.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Piscitelli J, Reddy MB, Wollenberg L, et al. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration. Clin Pharmacokinet. 2024. PMID: 38424308. doi:10.1007/s40262-024-01352-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。